Welcome to LookChem.com Sign In|Join Free

CAS

  • or

68401-81-0

Post Buying Request

68401-81-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

68401-81-0 Usage

Description

In ceftizoxime, the whole C-3 side chain has been omitted to prevent deactivation by hydrolysis. It rather resembles cefotaxime in its properties; however, not being subject to metabolism, its pharmacokinetic properties are much less complex.

Originator

Eposelin,Fujisawa,Japan,1982

Uses

Different sources of media describe the Uses of 68401-81-0 differently. You can refer to the following data:
1. Antibacterial.
2. Ceftizoxime is used for bacterial infections of the lower respiratory tract, infections of the urinary tract, infections of the bones, joints, skin, soft tissues, and abdominal infections. Synonyms of this drug are ceftix and eposerin.
3. Ceftizoxime is a cephalosporin based, potent antibacterial agent.

Definition

ChEBI: A parenteral third-generation cephalosporin, bearing a 2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino group at the 7beta-position.

Manufacturing Process

Phosphorus oxychloride (2.0 g) was added at one time at 5°C to 10°C to a suspension of 2-methoxyimino-2-(2-amino-1,3-thiazol-4-yl)acetic acid (syn isomer) (2 g) in dry ethyl acetate (20 ml). After stirring for 20 minutes at 7°C to 10°C, bis(trimethylsilyl)acetamide (0.4 g) was added thereto at the same temperature. After stirring for 10 minutes at 7°C to 10°C, phosphorus oxychloride (2.0 g) was dropwise added thereto at the same temperature. The resulting mixture was stirred for 10 minutes at 7°C to 10°C, and dry dimethylformamide (0.8 g) was dropwise added thereto at the same temperature. The mixture was stirred for 30 minutes at 7°C to 10°C to give a clear solution. On the other hand, trimethylsilylacetamide (7.35 g) was added to a suspension of 7-aminocephalosporanic acid (2.45 g) in dry ethyl acetate (8 ml), after which the mixture was stirred at 40°C to give a clear solution. To this solution was added at one time the above-obtained ethyl acetate solution at -15°C, and the resulting mixture was stirred for 1 hour at -10°C to -15°C. The reaction mixture was cooled to -30°C, and water (80 ml) was added thereto. The aqueous layer was separated, adjusted to pH 4.5 with sodium bicarbonate and subjected to column chromatography on Diaion HP-20 resin (Mitsubishi Chemical Industries Ltd.) using 25% aqueous solution of isopropyl alcohol as an eluent. The eluate was lyophilized to give 7-[2- methoxyimino-2-(2-amino-1,3-thiazol-4-yl)acetamido]cephalosporanic acid (syn isomer) (1.8 g), MP 227°C (decomp.).

Brand name

Cefizox (Astellas).

Therapeutic Function

Antibacterial

Antimicrobial activity

A semisynthetic cephalosporin supplied as the sodium salt. The properties are very similar to those of cefotaxime, but it lacks the acetoxymethyl group at position C-4 and is therefore not subject to deacetylation. Activity against common pathogenic bacteria (Table 13.4) is very similar to that of cefotaxime. A 500 mg intramuscular injection achieves a plasma concentration of around 14 mg/L. A concentration of 85–90 mg/L is produced 30 min at the end of a 30-min intravenous infusion. The plasma half-life is 1.3–1.9 h. Protein binding is 30%. It is well distributed. In children with meningitis receiving 200–250 mg/kg per day in four equally divided doses for 14–21 days, mean CSF concentrations 2 h after a dose were 6.4 mg/L on day 2 and 3.6 mg/L on day 14. About 70–90% of the dose is recovered in the urine in the first 24 h, principally by glomerular filtration. Probenecid increases the plasma half-life by about 50%. In patients receiving 1 g intravenously over 30 min, the plasma elimination half-life rose to 35 h when the corrected creatinine clearance was <10 mL/ min. It is partly removed by peritoneal and hemodialysis. Adverse reactions and clinical use are similar to those of cefotaxime.

Synthesis

Ceftizoxime, α-O-methyloxime of (6R,7R)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.64), is synthesized by the scheme described below, which begins with 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefem-4-carboxylic acid (32.1.2.57), which is synthesized using a number of methods used to synthesize cefaclor (32.1.2.48). Reducing the C3–C4 double bond in the initial 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefem- 4-carboxylic acid (32.1.2.57) with sodium borohydride in methanol, 4-nitrobenzyl ester of 3-hydroxy-7-(2-phenylacetamido)-3-cefam-4-carboxylic acid (32.1.2.58) is obtained, the hydroxyl group in which it is acylated by acetic anhydride in pyridine, forming acetate (32.1.2.59). Reacting this with triethylamine removes a molecule of acetic acid, giving the 4-nitrobenzyl ester of 7-(2-phenylacetamido)-3-cefem-4-carboxylic acid (32.1.2.60). Reacting this with phosphorous pentachloride in pyridine, followed by subsequent methanolysis deacylates the amide fragment of the molecule, giving the 4-nitrobenzyl ester of 7-amino- 3-cefem-4-carboxylic acid (32.1.2.61). Preliminary silylation of the amino group of this compound with trimethylsilylacetamide and subsequent acylation with 2-(2-formamido-4-thiazolyl)-2-methoxyminoacetic acid chloride synthesized directly in reaction conditions by reacting with phosphorous chloroxide in dimethylformamide gives the 4-nitro-benzyl ester of α-O-methyloxime of 7-[2-(2-formamido-4-thiazolyl)glyoxylamido]-8-oxo-t-thia-1-azabicyclo[4.2.0]oct-2-en-2-carboxylic acid (32.1.2.62). Reducing this with hydrogen using a palladium on carbon catalyst removes the 4-nitrobenzyl protection from the carboxyl group, forming the acid (32.1.2.63). Finally, hydrolysis of the formamide region of the molecule using hydrogen chloride in methanol gives the desired ceftizoxime (32.1.2.64).

Check Digit Verification of cas no

The CAS Registry Mumber 68401-81-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,8,4,0 and 1 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 68401-81:
(7*6)+(6*8)+(5*4)+(4*0)+(3*1)+(2*8)+(1*1)=130
130 % 10 = 0
So 68401-81-0 is a valid CAS Registry Number.
InChI:InChI=1/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-

68401-81-0 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2622)  Ceftizoxime  >98.0%(HPLC)(T)

  • 68401-81-0

  • 1g

  • 489.00CNY

  • Detail
  • TCI America

  • (C2622)  Ceftizoxime  >98.0%(HPLC)(T)

  • 68401-81-0

  • 5g

  • 1,680.00CNY

  • Detail
  • USP

  • (1098173)  Ceftizoxime  United States Pharmacopeia (USP) Reference Standard

  • 68401-81-0

  • 1098173-350MG

  • 4,662.45CNY

  • Detail

68401-81-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name ceftizoxime

1.2 Other means of identification

Product number -
Other names Ceftizoxima

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:68401-81-0 SDS

68401-81-0Synthetic route

(6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
36923-17-8

(6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

C13H10N4O2S3

C13H10N4O2S3

ceftizoxime
68401-81-0

ceftizoxime

Conditions
ConditionsYield
Stage #1: (6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid With dmap In dichloromethane at -8 - 0℃;
Stage #2: C13H10N4O2S3 With dmap In dichloromethane at -5 - 0℃; for 0.25h; Reagent/catalyst; Temperature;
97%
pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-carboxylate
68881-44-7

pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-carboxylate

A

ceftizoxime
68401-81-0

ceftizoxime

B

(2R,6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2-carboxylic acid
102044-69-9

(2R,6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2-carboxylic acid

C

(2R,6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

(2R,6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-3-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

Conditions
ConditionsYield
With water In N,N-dimethyl-formamide at 37℃; Rate constant; phosphate buffer, var. pH;
(6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
36923-17-8

(6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

(Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate
80756-85-0

(Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate

ceftizoxime
68401-81-0

ceftizoxime

Conditions
ConditionsYield
Stage #1: (6R,7R)-7-amino-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid With triethylamine In chloroform for 0.333333h;
Stage #2: (Z)-S-benzo[d]thiazol-2-yl 2-(2-aminothiazol-4-yl)-2-(methoxyimino)ethanethioate In chloroform at 35℃; for 4.5h; Temperature;
87 g
iodomethyl pivaloate
53064-79-2

iodomethyl pivaloate

ceftizoxime
68401-81-0

ceftizoxime

pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-carboxylate
68881-44-7

pivaloyloxymethyl 7β-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-cephem-4-carboxylate

Conditions
ConditionsYield
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification;73%
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCOCH3

XCH(CH3)OCOCH3

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester
84725-07-5

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester

Conditions
ConditionsYield
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification;
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2CH(CH3)2

XCH(CH3)OCO2CH(CH3)2

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester
84089-74-7

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester

Conditions
ConditionsYield
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification;
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2C2H5

XCH(CH3)OCO2C2H5

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester
84129-42-0

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester

Conditions
ConditionsYield
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification;
ceftizoxime
68401-81-0

ceftizoxime

but-2,3-en-2,3-carbonate-1-yl halide

but-2,3-en-2,3-carbonate-1-yl halide

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

Conditions
ConditionsYield
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification;
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
235099-09-9

(6R,7R)-7-{2-(2-Amino-thiazol-4-yl)-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester

Conditions
ConditionsYield
With N-cyclohexyl-cyclohexanamine In N,N-dimethyl acetamide at -5℃; for 2h; Esterification;
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-(2-tert-Butoxycarbonylamino-acetylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester
249552-46-3

(6R,7R)-7-{2-[2-(2-tert-Butoxycarbonylamino-acetylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

pivaloyloxymethyl 7β-[(Z)-2-[2-N-(tert-butoxycarbonyl)-(S)-alanylaminothiazol-4-yl]-2-methoxyiminoacetamido]-3-cephem-4-carboxylate
135790-89-5

pivaloyloxymethyl 7β-[(Z)-2-[2-N-(tert-butoxycarbonyl)-(S)-alanylaminothiazol-4-yl]-2-methoxyiminoacetamido]-3-cephem-4-carboxylate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: 50 percent / EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester
235099-14-6

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester
249552-52-1

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester
249552-47-4

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-3-methyl-butyrylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-3-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-3-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester
249552-48-5

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
235099-15-7

(6R,7R)-7-{2-[2-((S)-2-tert-Butoxycarbonylamino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-acetoxy-ethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-6-Amino-2-tert-butoxycarbonylamino-hexanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester
249552-50-9

(6R,7R)-7-{2-[2-((S)-6-Amino-2-tert-butoxycarbonylamino-hexanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-isopropoxycarbonyloxy-ethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

Ceftizoxime arapivoxil hydrochloride

Ceftizoxime arapivoxil hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: 50 percent / EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: 92 percent / HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-ethoxycarbonyloxy-ethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-(2-Amino-acetylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

(6R,7R)-7-{2-[2-(2-Amino-acetylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-3-methyl-butyrylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-3-methyl-butyrylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-4-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-4-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-3-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-3-methyl-pentanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; hydrochloride

(6R,7R)-7-{2-[2-((S)-2-Amino-propionylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester; hydrochloride

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme
ceftizoxime
68401-81-0

ceftizoxime

XCH(CH3)OCO2cHex

XCH(CH3)OCO2cHex

(6R,7R)-7-{2-[2-((S)-2,6-Diamino-hexanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; compound with GENERIC INORGANIC NEUTRAL COMPONENT

(6R,7R)-7-{2-[2-((S)-2,6-Diamino-hexanoylamino)-thiazol-4-yl]-2-[(Z)-methoxyimino]-acetylamino}-8-oxo-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 2,2-dimethyl-propionyloxymethyl ester; compound with GENERIC INORGANIC NEUTRAL COMPONENT

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: 73 percent / dicyclohexylamine / N,N-dimethyl-acetamide / 2 h / -5 °C
2: EDC*HCl; DMAP / CH2Cl2 / 2 h / 20 °C
3: HCl / formic acid; propan-2-ol / 0.08 h / 0 - 5 °C
View Scheme

68401-81-0Relevant articles and documents

Preparation method of ceftizoxime sodium and preparation method of ceftizoxime sodium intermediate

-

Paragraph 0037; 0045-0050, (2021/02/06)

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of ceftizoxime sodium and a preparation method of a ceftizoxime sodium intermediate. The preparation method of ceftizoxime sodium comprises the following steps of: adding 7-amino-3-cephalosporin-free 4-carboxylic acid diphenyl methyl ester and (E)- 2-(2-aminothiazole-4-yl)-2-(methoxyimino) acetic acid into a DMF solution, adding a condensing agent, reacting completely, adding water into the reaction solution, filtering to obtain ceftizoxime sodium intermediate filtrate, adding acid to adjust pH, and filtering and drying to obtain ceftizoxime acid; and suspending the ceftizoxime acid in water, adding sodium bicarbonate, adding activated carbon after dissolution of sodium bicarbonate,filtering to obtain filtrate, adding acetone, crystallizing, filtering and drying to obtain ceftizoxime sodium. According to the method, 7-amino-3- cephalosporin-free-4-carboxylic acid diphenyl methylester and (E)-2-(2-aminothiazole-4-yl)-2-(methoxyimino) acetic acid are directly condensed, a diphenyl methyl ester protecting group is removed by a one-step method, the process is safe and environment-friendly, the raw materials are low in price, and the quality of the obtained ceftizoxime sodium is superior to that of the ceftizoxime sodium prepared by the traditional process.

A one-head spore zuozuo wo sodium compound (by machine translation)

-

Paragraph 0027; 0028; 0034, (2019/01/17)

The present invention discloses a one-head spore zuozuo wo sodium compound, per mole of ceftizoxime sodium containing 1 mole water. The corresponding X-ray characteristic diffraction peaks of the 2 θ angle of the 11.43 ± 0.2 °, 13 . 24 ± 0.2 °, 16 . 54 ± 0.2 °, 17 . 86 ± 0.2 °, 19 . 45 ± 0.2 °, 20 . 66 ± 0.2 °, 22 . 33 ± 0.2 °, 22 . 88 ± 0.2 °, 23 . 29 ± 0.2 °, 23 . 66 ± 0.2 °, 24 . 59 ± 0.2 ° has a characteristic diffraction peak. The method of the invention by a water head preparation of spore zuozuo wo sodium compound, has good stability and meet the requirements as a raw material of a preparation. (by machine translation)

Studies on orally active cephalosporin esters. II. Chemical stability of pivaloyloxymethyl esters in phosphate buffer solution

Miyauchi,Sasahara,Fujimoto,Kawamoto,Ide,Nakao

, p. 2369 - 2374 (2007/10/02)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 68401-81-0